Study of a Five Years Survival Rate of Cancer in Sudanese
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
TRP Channels in Digestive Tract Cancers
International Journal of Molecular Sciences Review TRP Channels in Digestive Tract Cancers Paulina Stokłosa *, Anna Borgström, Sven Kappel and Christine Peinelt Institute of Biochemistry and Molecular Medicine, National Center of Competence in Research NCCR TransCure, University of Bern, 3012 Bern, Switzerland; [email protected] (A.B.); [email protected] (S.K.); [email protected] (C.P.) * Correspondence: [email protected]; Tel.: +0041-(0)31-631-34-26 Received: 10 February 2020; Accepted: 6 March 2020; Published: 9 March 2020 Abstract: Cancers of the digestive tract are among the most prevalent types of cancer. These types of cancers are often diagnosed at a late stage, which results in a poor prognosis. Currently, many biomedical studies focus on the role of ion channels, in particular transient receptor potential (TRP) channels, in cancer pathophysiology. TRP channels show mostly non-selective permeability to monovalent and divalent cations. TRP channels are often dysregulated in digestive tract cancers, which can result in alterations of cancer hallmark functions, such as enhanced proliferation, migration, invasion and the inability to induce apoptosis. Therefore, TRP channels could serve as potential diagnostic biomarkers. Moreover, TRP channels are mostly expressed on the cell surface and ion channel targeting drugs do not need to enter the cell, making them attractive candidate drug targets. In this review, we summarize the current knowledge about TRP channels in connection to digestive tract cancers (oral cancer, esophageal cancer, liver cancer, pancreatic cancer, gastric cancer and colorectal cancer) and give an outlook on the potential of TRP channels as cancer biomarkers or therapeutic targets. -
Cancer Survival in Qidong Between 1972 and 2011: a Population‑Based Analysis
944 MOLECULAR AND CLINICAL ONCOLOGY 6: 944-954, 2017 Cancer survival in Qidong between 1972 and 2011: A population‑based analysis JIAN-GUO CHEN1,2, JIAN ZHU1, YONG-HUI ZHANG1, YI-XIN ZHANG2, DENG-FU YAO3, YONG-SHENG CHEN1, JIAN-HUA LU1, LU-LU DING1, HAI-ZHEN CHEN2, CHAO-YONG ZHU2, LI-PING YANG2, YUAN-RONG ZHU1 and FU-LIN QIANG2 1Qidong Cancer Registry, Qidong Liver Cancer Institute, Qidong, Jiangsu 226200; 2Nantong University Tumour Hospital/Institute, Nantong, Jiangsu 226361; 3Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China Received May 17, 2016; Accepted March 7, 2017 DOI: 10.3892/mco.2017.1234 Abstract. Population-based cancer survival is an improved lung, colon and rectum, oesophagus, female breast and bladder index for evaluating the overall efficiency of cancer health cancer, as well as leukaemia and NHL. The observations of services in a given region. The current study analysed the the current study provide the opportunity for evaluation of observed survival and relative survival of leading cancer sites the survival outcomes of frequent cancer sites that reflects the from a population‑based cancer registry between 1972 and 2011 changes and improvement in a rural area in China. in Qidong, China. A total of 92,780 incident cases with cancer were registered and followed‑up for survival status. The main Introduction sites of the cancer types, based on the rank order of incidence, were the liver, stomach, lung, colon and rectum, oesophagus, Cancer survival is an index for evaluating the effect of treatment breast, pancreas, leukaemia, brain and central nervous system of patients in specific settings, whether used to define outcomes (B and CNS), bladder, blood [non‑Hodgkin's lymphoma in clinical trials or as an indicator of the overall efficiency of (NHL)] and cervix. -
Cancers Unequal Burden
The reality behind improving cancer survival rates April 2014 Cancer’s unequal burden – The reality behind improving cancer survival rates • Foreword • Executive summary • The reality behind improving cancer survival rates • Improving survival outcomes • Conclusion • References 3 Cancer’s unequal burden – The reality behind improving cancer survival rates in these areas has the potential to significantly reduce the overall cost of cancer care as well as greatly improving the lives of those with cancer. Routes from Diagnosis, developed in Survival rates for some cancers have soared over the past 40 years in England. partnership with strategy consultancy In the early 1970s, overall median survival time for all cancer types – the time Monitor Deloitte and Public Health by which half of people with cancer have died and half have survived – was just England’s National Cancer Intelligence i ii Network (NCIN), also shows us one year . Now it is predicted to be nearly six years , testament to the good work the value of linking and analysing of the NHS and advances in diagnosis, treatment and care. But there is a grim routinely collected NHS data. Only by reality hidden behind these numbers. combining data from cancer registries with hospital records have we been able to produce such a powerful picture of what happens to people New research led by Macmillan These new figures are taken from our after they are diagnosed with cancer Cancer Support reveals what happens groundbreaking Routes from Diagnosis and which groups of people in to people in England after they are research programme, which links particular need more support. -
Transient Receptor Potential (TRP) Channels in Haematological Malignancies: an Update
biomolecules Review Transient Receptor Potential (TRP) Channels in Haematological Malignancies: An Update Federica Maggi 1,2 , Maria Beatrice Morelli 2 , Massimo Nabissi 2 , Oliviero Marinelli 2 , Laura Zeppa 2, Cristina Aguzzi 2, Giorgio Santoni 2 and Consuelo Amantini 3,* 1 Department of Molecular Medicine, Sapienza University, 00185 Rome, Italy; [email protected] 2 Immunopathology Laboratory, School of Pharmacy, University of Camerino, 62032 Camerino, Italy; [email protected] (M.B.M.); [email protected] (M.N.); [email protected] (O.M.); [email protected] (L.Z.); [email protected] (C.A.); [email protected] (G.S.) 3 Immunopathology Laboratory, School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy * Correspondence: [email protected]; Tel.: +30-0737403312 Abstract: Transient receptor potential (TRP) channels are improving their importance in differ- ent cancers, becoming suitable as promising candidates for precision medicine. Their important contribution in calcium trafficking inside and outside cells is coming to light from many papers published so far. Encouraging results on the correlation between TRP and overall survival (OS) and progression-free survival (PFS) in cancer patients are available, and there are as many promising data from in vitro studies. For what concerns haematological malignancy, the role of TRPs is still not elucidated, and data regarding TRP channel expression have demonstrated great variability throughout blood cancer so far. Thus, the aim of this review is to highlight the most recent findings Citation: Maggi, F.; Morelli, M.B.; on TRP channels in leukaemia and lymphoma, demonstrating their important contribution in the Nabissi, M.; Marinelli, O.; Zeppa, L.; perspective of personalised therapies. -
Cancer Treatment and Survivorship Facts & Figures 2019-2021
Cancer Treatment & Survivorship Facts & Figures 2019-2021 Estimated Numbers of Cancer Survivors by State as of January 1, 2019 WA 386,540 NH MT VT 84,080 ME ND 95,540 59,970 38,430 34,360 OR MN 213,620 300,980 MA ID 434,230 77,860 SD WI NY 42,810 313,370 1,105,550 WY MI 33,310 RI 570,760 67,900 IA PA NE CT 243,410 NV 185,720 771,120 108,500 OH 132,950 NJ 543,190 UT IL IN 581,350 115,840 651,810 296,940 DE 55,460 CA CO WV 225,470 1,888,480 KS 117,070 VA MO MD 275,420 151,950 408,060 300,200 KY 254,780 DC 18,750 NC TN 470,120 AZ OK 326,530 NM 207,260 AR 392,530 111,620 SC 143,320 280,890 GA AL MS 446,900 135,260 244,320 TX 1,140,170 LA 232,100 AK 36,550 FL 1,482,090 US 16,920,370 HI 84,960 States estimates do not sum to US total due to rounding. Source: Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute. Contents Introduction 1 Long-term Survivorship 24 Who Are Cancer Survivors? 1 Quality of Life 24 How Many People Have a History of Cancer? 2 Financial Hardship among Cancer Survivors 26 Cancer Treatment and Common Side Effects 4 Regaining and Improving Health through Healthy Behaviors 26 Cancer Survival and Access to Care 5 Concerns of Caregivers and Families 28 Selected Cancers 6 The Future of Cancer Survivorship in Breast (Female) 6 the United States 28 Cancers in Children and Adolescents 9 The American Cancer Society 30 Colon and Rectum 10 How the American Cancer Society Saves Lives 30 Leukemia and Lymphoma 12 Research 34 Lung and Bronchus 15 Advocacy 34 Melanoma of the Skin 16 Prostate 16 Sources of Statistics 36 Testis 17 References 37 Thyroid 19 Acknowledgments 45 Urinary Bladder 19 Uterine Corpus 21 Navigating the Cancer Experience: Treatment and Supportive Care 22 Making Decisions about Cancer Care 22 Cancer Rehabilitation 22 Psychosocial Care 23 Palliative Care 23 Transitioning to Long-term Survivorship 23 This publication attempts to summarize current scientific information about Global Headquarters: American Cancer Society Inc. -
Erlotinib in the Treatment of Non-Small Cell Lung Cancer: Current Status and Future Developments
ANTICANCER RESEARCH 30: 1301-1310 (2010) Review Erlotinib in the Treatment of Non-small Cell Lung Cancer: Current Status and Future Developments CESARE GRIDELLI, PAOLO MAIONE, MARIA ANNA BARESCHINO, CLORINDA SCHETTINO, PAOLA CLAUDIA SACCO, RITA AMBROSIO, VALENTINA BARBATO, MARZIA FALANGA and ANTONIO ROSSI Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy Abstract. Erlotinib is an orally small molecule inhibiting The epidermal growth factor receptor (EGFR) is one of the tyrosine kinase activity of the epidermal growth factor the most studied targets for cancer therapy. The present receptor (EGFR). Currently, erlotinib, at a standard oral review discusses the role of erlotinib, an anti-EGFR tyrosine daily dose of 150 mg, is licensed for the treatment of kinase inhibitor (TKI), in the treatment of NSCLC. unselected recurrent non-small cell lung cancer (NSCLC) patients, however, it is being investigated in all stages of Epidermal Growth Factor Receptor Pathway NSCLC. Erlotinib is well tolerated, with common toxicities including rash and diarrhoea. The optimization of the The EGFR, also known as ErbB-1/HER1, is the first of four therapeutic impact of erlotinib in NSCLC will be more members of the ErbB family of cell membrane receptors, defined when reliable predictive factors are identified. An which are important mediators in cell growth, differentiation, important step has been made in the molecular and survival (3, 4). The EGFR is known to bind with a high characterization of potentially sensitive NSCLC patients. In affinity to several ligands including EGF, amphiregulin and fact, we have learned that activation, somatic EGFR gene transforming growth factor α (TGFα). -
No. 59C November 27, 2014 (Sel) Largest Worldwide Study on Cancer
No. 59c November 27, 2014 (Sel) Largest worldwide study on cancer survival rates reveals dramatic differences – Germany among the leading countries worldwide In a study called CONCORD-2, around 500 international scientists report on 5-year survival rates for about 25.7 million adult cancer patients suffering from one of the ten most common types of cancer (stomach, colon, rectum, liver, lung, breast, cervix, ovaries, prostate, leukemia) as well as for approximately 75,000 children who were diagnosed with acute lymphoblastic leukemia (ALL) between 1995 and 2009. In the study, the scientists drew on data from 279 cancer registries in 67 countries. It was analyzed using a method called period analysis, developed by Hermann Brenner from the German Cancer Research Center (DKFZ) in Heidelberg. This method delivers more up-to-date data on long-term survival than the rates obtained by conventional methods. The study was published in the journal “Lancet”. The scientists noted major differences in survival rates in various countries for specific cancer types. This also held true after taking into account regional differences in life expectancy due to other factors such as the age, gender or race of subjects in the study. Above all, they identified remarkable variations in 5-year survival rates for children with acute lymphoblastic leukemia: Rates ranged from 16-50% in countries such as Jordan, Lesotho, Tunisia, Indonesia, and Mongolia to over 90% in Canada, Austria, Belgium, Germany and Norway. In their report the scientists state that this shows large deficits in the management of a disease for which in fact there are effective treatments. -
Occupational Cancer in Britain Remaining Cancer Sites: Brain, Bone, Soft Tissue Sarcoma and Thyroid
British Journal of Cancer (2012) 107, S85 – S91 & 2012 Cancer Research UK All rights reserved 0007 – 0920/12 www.bjcancer.com Full Paper Occupational cancer in Britain Remaining cancer sites: brain, bone, soft tissue sarcoma and thyroid Terry Brown3, Charlotte Young2 and Lesley Rushton*,1 with the British Occupational Cancer Burden Study Group 3 2 Institute of Environment and Health, Cranfield Health, Cranfield University, Cranfield MK43 0AL, UK; Health and Safety Laboratory, Harpur Hill, 1 Buxton, Derbyshire SK17 9JN, UK; Department of Epidemiology and Biostatistics, School of Public Health and MRC-HPA Centre for Environment and Health, Imperial College London, St Mary’s Campus, Norfolk Place, London W2 3PG, UK British Journal of Cancer (2012) 107, S85–S91; doi:10.1038/bjc.2012.124 www.bjcancer.com & 2012 Cancer Research UK Keywords: occupation; brain; bone; thyroid OVERVIEW OF CANCERS in men and 14% in women, with that for men showing a significant improvement since 1986–1990. This paper reviews the four cancer sites: brain, bone, sarcoma and thyroid, which do not fit readily into the organ-specific groups defined for the other papers in this supplement. Ionising radiation Bone cancer is a cause of cancers of both the bone and thyroid, and thus this exposure will be considered together in the relevant section. Cancers that arise in the bone or articular cartilage account for B0.5% of all malignant neoplasms in humans (Miller et al, 2006). In Britain, over recent years, the number of cancers registered has Brain and central nervous system (CNS) cancers been relatively stable, whereas the number of people who died Primary brain and CNS cancers are rare. -
Surgical Management of Gastric Cancer: a Systematic Review
Journal of Clinical Medicine Review Surgical Management of Gastric Cancer: A Systematic Review Lucian Mocan 1,2 1 Department of Surgery, Iuliu Hatieganu University of Medicine and Pharmacy, RO-400012 Cluj-Napoca, Romania; [email protected] or [email protected]; Tel.: +40-745-362-345 2 Regional Institute of Gastroenterology and Hepatology, 19-21 Croitorilor Street, RO-400162 Cluj-Napoca, Romania Abstract: Gastric cancer is the fifth most common cancer worldwide, and it is responsible for 7.7% of all cancer deaths. Despite advances in the field of oncology, where radiotherapy, neo and adjuvant chemotherapy may improve the outcome, the only treatment with curative intent is represented by surgery as part of a multimodal therapy. Two concepts may be adopted in appropriate cases, neoadjuvant treatment before gastrectomy (G) or primary surgical resection followed by chemotherapy. Such an approach, combined with early detection and better screening, has led to a decrease in the overall incidence of gastric cancer. Unfortunately, malignant tumors of the stomach are often diagnosed in locally advanced or metastatic stages when the median overall survival remains poor. Surgical care in these cases must be provided by a multidisciplinary team in a high-volume center. Important surgical aspects such as optimum resection margins, surgical technique, and number of harvested lymph nodes are important factors for patient outcomes. The standardization of surgical treatment of gastric cancer in accordance with the patient’s profile is of decisive importance for a better outcome. This review aims to summarize the current standards in the surgical treatment of gastric cancer. Keywords: gastric cancer; surgery; lymphadenectomy; survival Citation: Mocan, L. -
Expression and Prognostic Significance of TRPV6 in the Development and Progression of Pancreatic Cancer
1432 ONCOLOGY REPORTS 39: 1432-1440, 2018 Expression and prognostic significance of TRPV6 in the development and progression of pancreatic cancer HE SONG, MING DONG, JIANPING ZHOU, WEIWEI SHENG, XIN LI and WEI GAO Department of Gastrointestinal Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China Received June 20, 2017; Accepted January 3, 2018 DOI: 10.3892/or.2018.6216 Abstract. In this study, we aimed to clarify the expression and tumor-suppressor. Nevertheless, the expression and biological biological functions of TRPV6 in human pancreatic cancer functions of TRPV6 in PC are less fully elucidated. Therefore, (PC) tissue and pancreatic cancer (PC) cell lines. TRPV6 was we analyzed the expression of TRPV6 for clinicopathological up-regulated in the primary cancer tissues from pancreatic characteristics, predicting survival in the patients, and the effect cancer (PC) patients. TRPV6 may regulate multiple proteins of silencing TRPV6 on apoptosis, proliferation, cell cycle, related to apoptosis, cell cycle and metastasis pathways. migration, invasion and chemotherapy sensitivity of PC cells, Silencing TRPV6 significantly inhibited invasion, prolifera- respectively, to gemcitabine, oxaliplatin and cisplatin. TRPV6 tion and migration and induced apoptosis and cell cycle arrest. plays a promising role in the development and progression of TRPV6 plays a promising role of an oncogene in pancreatic PC. Numb was originally discovered as a determinant of cell carcinogenesis and represents the new potential biomarker for fate (10) responsible for plenty of signal transduction pathways PC. (Hedgehog, P53), endocytosis, cell polarity determination, and ubiquitination (11), and to play an important role in cancers. Introduction Numb was recently found as a new interacting partner with TRPV6 (12). -
Malignant Paraganglioma
[Jurn ery alu rg l d u e S C f h o i l r Journal of Surgery u a r n g r i u e o ] J ISSN: 1584-9341 [Jurnalul de Chirurgie] Case Report Open Access Malignant Paraganglioma; a Story of a Long Time Survival Ioana Vasiliu1, Bogdan Hancearuc1, Dan Iliescu2, Cipriana Ștefănescu3, Radu Popa4, Delia Ciobanu5, Letiţia Leuştean1, Voichita Mogoș1 and Carmen Vulpoi1* 1Department of Endocrinology, University of Medicine and Pharmacy “Grigore T. Popa” Iași, Romania 2Department of Cardiology, University of Medicine and Pharmacy “Grigore T. Popa” Iași, Romania 3Department of Nuclear Medicine, University of Medicine and Pharmacy “Grigore T. Popa” Iași, Romania 4Department of Vascular Surgery, University of Medicine and Pharmacy “Grigore T. Popa” Iași, Romania 5Department of Pathology, University of Medicine and Pharmacy “Grigore T. Popa” Iași, Romania Abstract Pheochromocytoma and paraganglioma are catecholamine secreting tumors. Malignancy is uncommon - ap- proximately 10% for pheochromocytoma and 20% for paraganglyoma. Surgery, when possible, is the first line treatment. Prognosis is poor because of a frequent local recurrence and/or metastases and the lack of specific chemotherapeutic agents. We report the case of a 60 years old man who was hospitalized at the age of 48 for episodes of paroxystic hypertension with spells. The high levels of vanillylmandelic acid (VMA), more than 50 mg/24h at 3 determinations, confirmed the excess of catecholamine, but the CT scan failed to reveal the tumor. The iodine-131- meta-iodobenzylguanidine (I-MIBG) scintigraphy showed the presence of a 1.5 cm nodule in the left abdominal para- aortic region. -
Breast Cancer Relative Survival 1985-2014
No: 2018/02 Statistical series: 108 The Cancer Effect An “Exploring Cancer” Series Western Australia Breast Cancer Relative Survival 1985–2014 Western Australia Cancer Registry and the Epidemiology Branch WA Department of Health WA Cancer Registry The WA Cancer Registry is part of the Department of Health (WA). The Registry records all cancer notifications (i.e. cancer diagnoses) for WA residents. The notification (reporting) of cancers, by pathologists and radiation oncologists (amongst others), to the Department of Health has been a legal requirement under the Health (Miscellaneous Provisions) Act 1911 since 1981. These current regulations are available as Health (Western Australian Cancer Register) Regulations 2011. Acknowledgements The Epidemiology Branch of the Department of Health WA designed the analysis tools used in this relative survival analysis study as well as conducting the analysis. The Epidemiology Branch also provided the WA Cancer Registry feedback on the report. The WA Cancer Registry also extends thanks to the individuals across the WA Department of Health who contributed to the production of this report. Contact regarding enquiries and additional information Telephone: +61 (0) 08 9222 4022 Email: [email protected]. Recent releases 2017/01 ALL Cancers Survival 2010-2014 The Cancer Effect—Breast Cancer survival 2010-14 2 Contents 1.0 Introduction ............................................................................................. 4 2.0 Incidence of breast cancer in WA .........................................................